[Market Focus] Kolon TissueGene Shares Jump Over 6% on "Therapy Value Reassessment"
The share price of Kolon TissueGene surged by more than 6%. There are also forecasts that the stock will rise further, as the value of Kolon TissueGene’s therapy is now considered higher than before.
As of 10:57 a.m. on January 27, Kolon TissueGene was trading at 996,000 won, up 57,000 won (6.07%) from the previous session.
Korea Investment & Securities announced on this day that it had recalculated the U.S. wholesale price of TG-C, Kolon TissueGene’s cell and gene therapy for knee osteoarthritis, which had previously been estimated conservatively, and raised its target price by 13% to 1.7 million won.
Research analysts Haejoo Wi and Dayong Lee from Korea Investment & Securities stated, “We have raised the valuation of TG-C in the U.S. by 15% to 9.9 trillion won, and adjusted the wholesale price for the first and second year after launch to $30,000 (about 40 million won), higher than the previous estimate of $15,000 to $28,000. Considering that the estimated price of Medipost’s ‘Cartistem’ for severe knee osteoarthritis, which is about to be commercialized in Japan, is 30 million won, and Vericel’s autologous cartilage cell implant ‘MACI’ is sold for up to $40,000 in the U.S., the pricing of TG-C is reasonable.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
They further explained, “The unique value of TG-C is reflected in the fact that drug prices in the U.S. are 2.5 times higher than those in OECD countries, and that TG-C is the only therapy that reduces the frequency of artificial joint surgery by maintaining efficacy for more than two years with a single injection.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.